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Patient selection for laparoscopic excision of adrenal 
metastases: a multicenter cohort study 
ABSTRACT:
Introduction: The use of laparoscopy for the excision of adrenal metastasis remains controversial.
We aimed to report oncological and perioperative outcomes of laparoscopic excision of adrenal 
metastases and to seek for predictive factors of unfavourable oncological outcomes. 
Methods: A retrospective chart review was conducted and all consecutive patients who underwent 
laparoscopic adrenalectomy (LA) in the setting of metastatic cancer in two academic urology 
departments from November 2006 through January 2014 were included. Primary tumors were 
categorized as pulmonary, renal or “other primary” tumors to allow statistical comparison. 
Unfavourable surgical outcomes were defined as the occurrence of either postoperative complications 
and/or positive surgical margins.  
Results: Forty-three patients who underwent a total of 45 LA were included for analysis. There were 
8 complications (17.8%). Positive surgical margins were found in 12 specimens (26.7%). After a 
median follow-up of 37 months, estimated overall survival rates were 89.5% and 51.5% at 1 year and 
5 years, respectively. In multivariable analysis the only predictor of unfavourable surgical outcomes 
was a tumor size > 5 cm (OR= 20.5; p=0.001). In multivariate analysis the pulmonary (OR=0.3; 
p=0.008) or “other” (OR= 0.1; p=0.0006) origin of the primary tumor was the only prognostic factor 
of shorter cancer specific survival. 
Conclusion: Laparoscopic resection of adrenal metastasis can be safely performed in most patients 
but is associated with an increased risk of positive surgical margins and postoperative complications in 
larger tumors (> 5 cm). Adrenalectomy provides better oncological outcomes in metastases from renal 
cell carcinoma compared to other primary tumors. 
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1. Introduction 
Despite a low level of evidence, adrenalectomy is now recommended in case of isolated adrenal 
metastasis [1-2], as many retrospective series have shown the oncological benefit of surgical excision 
in this situation [3].  
Firstly reported by Gagner et al. in 1992 [4], laparoscopic adrenalectomy (LA) has become the gold-
standard treatment of benign adrenal tumors. Several series have proven the lower morbidity of this 
approach in adrenal surgery (notably decreased complication rate and blood loss, shorter length of 
stay) [5-6]. Although most of the series of LA have shown similar surgical and oncological outcomes 
to those reported in the open era [7-8], the role of laparoscopy in the treatment of malignant adrenal 
tumors remains controversial. In recent years, two series have raised concern about the laparoscopic 
approach for resection of adrenal metastases. In a single center cohort of 16 patients, Sebag et al. noted 
high rates of positive surgical margins, complications and conversion to open surgery [9]. In their 
single-center series of 13 patients, Crenn et al reported similar findings [10].  
In this work, we therefore hypothesized that both the adrenal resection in itself and the laparoscopic 
approach could not be beneficial for every patient with isolated adrenal metastasis. We aimed to report 
oncological and perioperative outcomes of laparoscopic excision of adrenal metastases and to look for 
predictive factors of unfavourable surgical outcomes in order to determine which patients could 
benefit of laparoscopic resection of adrenal metastases.  
    2. Patients and methods 
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a. Study design 
A retrospective chart review was conducted to include all consecutive patients treated by LA in the 
setting of metastatic cancer in two academic urology departments, from November 2006 through 
January 2014. Adrenalectomies performed as part of radical nephrectomy or for extra adrenal tumor 
with local extension to the adrenal gland were excluded. All patients were treated with curative intent. 
The study received approval of the local ethics committees (Unique Identifying Number (UIN) from 
the Research Registry: 538).  
 Variables collected included patients’ characteristics (age, gender, ASA score, Body Mass Index), 
tumor related data (primary tumor, size, laterality, synchronous or metachronous, isolated or 
oligometastatic disease, adjuvant treatments), surgeon’s experience (categorized as: < 30 cases of LA 
or > 30 cases of LA), perioperative outcomes (operative time, intra and postoperative complications, 
blood loss, length of stay, surgical margins, conversion) and oncological outcomes (recurrence, date of 
recurrence and death, causes of death, recurrence location, date of last follow-up visit). Complications 
were graded according to Clavien-Dindo classification [11] and reported with full respect of the EAU 
guidelines on reporting complications [12]. Metastases were considered as synchronous if detected 
within 6 months after treatment of the primary tumor. Otherwise, they were defined as metachronous. 
Diseases were categorized as isolated (only one adrenal metastasis) or oligometastatic (other 
synchronous metastasis or history of previous metastasis). Unfavourable surgical outcomes were 
defined as the occurrence of either postoperative complications and/or positive surgical margins. 
Primary tumors were categorized as pulmonary, renal or “other primary” tumors to allow statistical 
comparison between groups. Tumors sizes were categorized as > 5cm or ? 5 cm. 
Our main objective was to determine predictors of unfavourable surgical and oncological outcomes. 
Our secondary objective was to report outcomes of LA in a multicenter study.?
                            b. Surgical techniques 
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All surgeries were performed laparoscopically. However, some procedures were performed through a 
transperitoneal approach whereas others were carried out by a retroperitoneal route. The choice of 
either the transperitoneal or retroperitoneal approach was left to surgeon’s discretion. In one of the 
department all LA were performed through a transperitoneal approach while both approaches were 
used in the other department. 
    
                          c. Patients follow-up?
All patients were evaluated by their surgeon at an outpatient appointment 1 month after surgery. All 
complications occurring during the first post-operative month were collected and considered as 
postoperative complications. Further oncological follow-up was then left to the oncologist and 
involved a physical examination and imaging every six months during the first two years and then 
annually for a minimum of 5 years. 
                           d. Statistical Analysis 
Means and standard deviations were reported for continuous variables and proportions for qualitative 
and categorical variables. Comparisons between groups were performed using ?2 test and Fisher 
exact test for discrete variables and student t test for continuous variables. To confirm the findings of 
univariate analysis, a logistic regression model was used to assess predictors of unfavourable surgical 
outcomes. Overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS) 
were estimated using the Kaplan-Meier method and compared with the log-rank test. A Cox 
proportional hazards regression model was used to define the prognostic factors. Statistical analyzes 
were conducted using JMP v.10.0 software (SAS Institute Inc, Cary, NC, USA). All tests were two-
sided with a significance level at p< 0.05. 
?
      3. Results 
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  a.  Patients’ characteristics 
Forty-three patients who underwent a total of 45 LA (2 cases of bilateral metastases: 1 renal carcinoma 
and 1 neuroendocrine tumor) were included for analysis. Mean age was 60.8 years (± 9.6) with 79.1% 
of male patients. Mean tumor size was 48.3 mm (±34.7). Primary tumors were renal carcinoma in 20 
cases (44.4%), non-small cell lung cancer in 11 cases (24.4%), colorectal cancer in 3 cases (6.7%), 
bladder cancer in 3 cases (6.7%), melanoma in 3 cases (6.7%), neuroendocrine tumor in 2 cases 
(4.4%), glandular eye carcinoma in 1 case (2.2%) and breast cancer in 1 case (2.2%). All surgeries 
were performed laparoscopically, 14 (31.1%) through a retroperitoneal route and 31 (72.1%) via a 
transperitoneal approach, Twenty-four procedures (55.8%) were performed by highly experienced 
surgeons (? 30 cases) and 19 (44.2%) by less experienced surgeons (< 30 cases). Twenty-seven 
patients (62.8%) had isolated adrenal metastasis and 16 (37.2%) had a history of previous metastasis 
(oligometastatic disease). Eight metastases were considered as synchronous (17.8 %). A PET scan was 
requested in 15 patients (37.5%) and showed a localized hypermetabolic activity in 13 cases (86.7%) , 
which reinforced the hypothesis of an isolated adrenal metastasis. 
b. Surgical outcomes 
Surgical outcomes are summarized in table 1. Mean operative time was 162.2 minutes (± 75.1). Eight 
complications occurred (17.8%): 4 blood transfusions due to intraoperative blood loss (Clavien grade 
2); 1 pulmonary infection (Clavien grade 2); 1 reoperation due to bleeding of the adrenal resection bed 
(Clavien grade 3B); 1 septic shock due to gallbladder perforation unnoticed intraoperatively (Clavien 
grade 4A) and 1 mesenteric ischemia resulting in a fatal outcome on postoperative day 4 (Clavien 5). 
Positive surgical margins were found in 12 specimens (26.7%). Conversion to open surgery was 
needed in 7 procedures (15.6%): because of important bleeding in 4 cases, of caval invasion in 2 
patients and due to gastric perforation in another patient.  
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c. Oncological outcomes 
After a median follow-up of 37 months (range: 1-94), estimated overall survival rates following 
adrenalectomy were 89.5% and 51.5% at 1 year and 5 years, respectively (see figure 1 a). Estimated 
cancer specific survival (CSS) rates were 89.5% and 53.3% respectively 1 year and 5 years after 
surgery (see figure 1b). Thirteen patients passed away during follow-up: eleven from disease, one 
from post-operative complications (mesenteric ischemia) and one from acute heart failure 21 months 
after surgery. This latter patient had a history of valvular disease and had no evidence of disease 
recurrence at the time of death. In the subgroup of 15 patients who had a minimum follow up of 5 
years: 8 were alive with no evidence of disease (53.3%) while 7 died from disease (47.7%) 1 to 5 
years following adrenalectomy.  
During follow-up, 24 patients had recurrence of disease (55.8%). The median recurrence-free survival 
was 17 months. Estimated recurrence free survival (RFS) rate was 65.4% and 26.4% at 1 year and 5 
years after surgery, respectively (see figure 1c). 
Recurrence consisted in distant metastasis in 22 cases (mostly lung, bone and brain metastases), in 
local recurrence in the adrenal resection bed in one case and in retroperitoneal carcinomatosis in one 
case. The latter two patients had large adrenal metastasis (79 and 120 mm respectively). They 
underwent conversion to open surgery due to intraoperative bleeding and both had positive surgical 
margins on final pathology.  
d. Predictive factors of unfavourable surgical outcomes 
Positive surgical margins and/or post-operative complications occurred in 15 patients (34.9%) who 
were considered to have unfavourable surgical outcomes. Patients with unfavourable surgical 
outcomes had larger tumors (69.4 vs. 36.6 mm; p=0.002) and were more likely to have “other 
primary” tumors (53.3% vs. 14.3%; 0.02). There was a trend towards a higher risk of unfavourable 
surgical outcomes in patients operated via a retroperitoneal route (50% vs. 29%; p=0.2) or when 
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adrenalectomy was performed by a less-experienced surgeon (47.4% vs. 25%; p= 0.13). In univariate 
analysis, only “other primary tumors” (pulmonary cancer: OR= 0.2, p=0.04; renal cancer: OR=0.1, 
p=0.01) and tumor size > 5 cm (OR= 16; p=0.0002) were predictive factors of a negative surgical 
outcome (see table 2). In multivariable analysis that adjusted for age, ASA score, surgeon’s 
experience, laparoscopic route, and types of primary tumor, the only predictor of negative surgical 
outcomes was a tumor size > 5 cm (OR= 20.5; p=0.001) but there was still a tendency towards better 
surgical outcomes in patients whose primary tumor was a pulmonary cancer (OR= 0.1; p=0.06) or 
renal cancer (OR=0.2; p=0.1) compared to patients with other primary tumors (see table 2). 
e. Prognostic factors of survival 
Patients with negative surgical margins (p=0.04), those with metastasis size ? 5cm (p=0.03), and those 
with a renal origin of the primary tumor (p=0.002) had longer CSS (see figure 1 d). In multivariate 
analysis the pulmonary (OR=0.3; p=0.008) or “other” (OR= 0.1; p=0.0006) origin of the primary 
tumor was the only prognostic factor of shorter CSS (see table 3). No prognostic factors of recurrence 
free survival (RFS) were found in either univariate or multivariate analysis. In the subgroup of adrenal 
metastasis from renal carcinoma (19 Patients, 20 metastasis), estimated 5-year CSS and RFS were 
100% and 21.3% respectively. 
4. Discussion 
Surgical resection of adrenal metastasis has gained wide acceptance over the past decade in case of 
isolated or oligometastatic disease and is now considered as the standard treatment in this situation [1-
3]. However there is a paucity of data to support this management and no randomized evidence to 
suggest that local therapy of adrenal metastases alters the natural course of the disease [13]. In the only 
large case-control study to date, Vazquez et al compared survivals of their patients treated with 
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adrenalectomy for adrenal metastasis to those of SEER-database stage-matched patients with no 
resection of adrenal metastases. They found a survival benefit in favour of surgical resection for 
metastases arising from lung, kidney, pancreas and sarcoma but their findings are debatable due to 
their study design [14]. Our results reinforce those previously reported in the literature by showing 
that resection of adrenal metastases may be associated with prolonged survival (5-year CSS and RFS 
rates: 53.3% and 26.4%, respectively) [3, 7-10, 13-14]. However, our 5-year CSS rate exceeds those 
reported in other series (from 30 to 40%) [3, 7-10, 13-14]. This may be due to the larger proportion in 
our series of patients with renal cell carcinoma who have been shown to have a significantly better 
prognosis compared with other primary tumors [8, 15-16].  
To date, only 5 series analyzed prognostic factors for resected adrenal metastases using a Cox 
regression model [8, 15-18].  Out of these studies, three showed a better prognosis in multivariate 
analysis for metastases from renal carcinoma [8, 15-16]. Our results confirm that a primary renal 
tumour is the main prognostic factor in surgical excision of adrenal metastases. Conversely, we did not 
find a prognostic impact for factors such as tumor size, type of treatment of the primary tumor 
(surgery, radiotherapy, …) or status of margins, which have ever been reported by others [8, 15-18]. 
This could be due to the relatively small sample size of our study.  
The present study is the first to report complications of surgery of adrenal metastases in a standardized 
way (i.e. using Clavien score [11], with respect of the EAU guidelines [12]). We report a complication 
rate similar to those previously published in the literature: 17.8% in our series versus 4 to 20% in other 
laparoscopic series [7, 9, 15, 18-19]. These complications rates seem overall comparable to the 
complication rates of open surgical adrenalectomies (6 to 20% [13,18]) but no firm conclusions can be 
established due to the lack of standardization of the complications report in most studies.  
In our study we used the concept of an unfavourable surgical outcome in the presence of post-
operative complications and/or positive surgical margins. Postoperative complications are indeed the 
most frequently used surrogate marker of quality in surgery [20] and on the other hand, positive 
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surgical margins have been show to negatively impact the oncological outcome in case adrenalectomy 
for metastasis [15,17] 
We found that a metastasis size > 5 cm was the only predictor of an unfavourable surgical outcome in 
multivariate analysis. Most authors advocate an open surgical approach for the excision of bigger 
lesions however the upper limit proposed for a laparoscopic approach varies in different studies [21-
22]. While it is quite obvious that excision of bigger lesions will involve a higher risk of complications 
and positive surgical margins, there is no firm evidence that an open approach would obtain a better 
surgical outcome. Our series similarly to most other published series did not have a control group and 
could not answer this question [3].  Due to the non-controlled design of our study we could not bring 
new evidence concerning the potential survival benefits of resection of adrenal metastasis compared to 
a non-surgical management. Another limitation of the present study is its retrospective nature, which 
can introduce selection and ascertainment bias. Finally, systemic therapies that have been shown to 
impact prognosis in other studies [17] were not taken into account in our series.?
5. Conclusion 
Laparoscopic resection of adrenal metastasis can be safely performed in most patients but is associated 
with an increased risk of positive surgical margins and of postoperative complications in larger tumors 
(size ? 5 cm). Adrenalectomy for metastasis can be associated with a prolonged survival in selected 
patients and provide better oncological outcomes in metastases from renal cell carcinoma compared to 
other primary tumors. 
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Table 1: perioperative parameters (n=45) 
?
Operative time (min) 162.2  (± 75.1) 
     Mean +/- SD  
Estimated Blood loss (ml) 288  (± 550) 
     Mean +/- SD  
Complications 
   N (%) 
             Clavien 2 5 (11.6%) 
             Clavien 3B 1 (2.3%) 
             Clavien 4A 1 (2.3%) 
             Clavien 5  1 (2.3%) 
Surgical margins
   N (%) 
            positive 12 (26.7%) 
            negative 33 (73.3%) 
Length of stay (days) 4.6 (±3.2) 
   N (%) 
Open Conversion 7 (15.5%) 
   N (%) 
Negative surgical outcome 15 (34.9%) 
   N (%) 
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Table 2: Predictive factors of unfavourable surgical outcome: univariate and 
multivariate analysis 
?
?
Variables 
Negative surgical outcome
Univariate analysis Multivariate analysis
Odds- 
Ratio 
Confidence  
Interval 95 % P-value 
Odds-
ratio 
Confidence 
Interval 95 % P-value 
Lower Upper Lower Upper 
Age (years) 2.5 0.2 36.8 0.47 1.9 0.05 79.3 0.71 
Surgeon’s 
experience 
< 30 cases 
> 30 cases
       
1 [ref] 
0.3 
- 
0.1 
- 
1.3 
0.13 1 [ref] 
0.5 
- 
0.1 
- 
3.4 
0.48 
Laparoscopic route 
Transperitoneal 
Retroperitoneal 
1 [ref] 
2.4 
- 
0.6 
- 
9.9 
0.2 1 [ref] 
4.8 
- 
0.6
- 
52.6 
0.15 
Primary tumor 
Other 
Lung cancer 
Renal cancer 
1 [ref] 
0.2 
0.1 
- 
0.02 
0.02 
- 
0.9 
0.6 
- 
0.04* 
0.01* 
1 [ref] 
0.1 
0.2 
- 
0.01 
0.01 
- 
1.1 
1.4 
- 
0.06 
0.1 
Tumor size 
? 5 cm 
> 5cm 
1 [ref] 
16 
- 
3.6 
- 
94.7 
0.0002* 1 [ref] 
20.5 
- 
3.1 
- 
237 
0.001* 
ASA score 1.4 0.2 12 0.71 0.7 0.02 14.6 0.79 
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Table 3: Prognostic factors of cancer-specific survival: multivariate 
analysis 
Cancer-specific survival 
Hazard 
Ratio 
Confidence Interval 95% 
p-value 
Lower Upper 
Age 0.9 0.1 12.6 0.93 
Tumor size 
? 5cm 
> 5cm 
1[Ref]  
0.4 
- 
0.1 
- 
3.5 
0.4 
Surgical margins 
Negative 
positive
1[Ref] 
0.7 
- 
0.1 
- 
6.7 
0.74 
Metastasis 
Synchronous 
Metachronous 
1[Ref] 
0.9 
- 
0.1
- 
18.6 
0.95 
Status 
Isolated metastasis 
Oligometastatic 
1[Ref] 
0.7 
- 
0.1
- 
2.6
0.59 
Primary tumor 
Renal cancer 
Lung cancer 
Other 
1[Ref] 
0.3 
0.1 
- 
0 
0
- 
0.4 
0.2 
0.008* 
0.0006*
Surgeon’s experience 
< 30 cases 
? 30 cases 
1[Ref] 
0.2 
- 
0.04 
- 
1.2 
0.08 
Laparoscopic route 
Transperitoneal 
Retroperitoneal 
1[Ref] 
2 
- 
0.4 
- 
12.3 
0.43 
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Figure 1: Survival curves 
?
???
?
Fig 1a: Estimated overall survival 
?
?
?
?
Fig 1b: Estimated cancer-specific survival 
?
?
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Fig 1 c: Estimated recurrence-free survival 
 
 
 
 
 
 
Figure 1 d: Cancer-specific survival according to the origin of primary tumor 
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2 : renal cancer 
3 : pulmonary cancer 
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Highlights 
• Positive surgical margins and complications rates were 26.7% and 17.8% respectively 
• Tumor size >5 cm was the only predictor of positive margins and/or complication 
• Non renal origin of the primary tumor was the only survival prognostic factor  
